Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival.

Biochemical and biophysical research communications - 28 May 2020

Hirai Sachie, Tada Makoto, Yamaguchi Miki, Niki Toshiro, Sakuma Yuji

Abstract excerpt

Although most EGFR-mutant lung adenocarcinomas initially respond to EGFR inhibitors, disease progression almost inevitably occurs. We previously reported that two EGFR-mutant lung adenocarcinoma cell lines, HCC827 and H1975, contain subpopulations of cells that display an epithelial-to-mesenchymal phenotype and can thrive independently of EGFR signaling. In this study, we explored to what extent these two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to bcl-X Protein

Share to Cell Survival

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to Gene Silencing

Share to Myeloid Cell Leukemia Sequence 1 Protein

Source

Identifiers

PMID: 32223928
DOI: 10.1016/j.bbrc.2020.03.116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival.PMID 32223928Read ↗

Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.Semantic proximity Read ↗

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.Semantic proximity Read ↗

EGFR signaling and autophagy dependence for growth, survival, and therapy resistanceSemantic proximity Read ↗

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.Semantic proximity Read ↗

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expressionSemantic proximity Read ↗

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.Semantic proximity Read ↗

Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancerSemantic proximity Read ↗

Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosisSemantic proximity Read ↗

Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.Semantic proximity Read ↗

Co-targeting BCL-X <sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in miceSemantic proximity Read ↗

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.Semantic proximity Read ↗

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.